ValRS Inhibitors

Chemical inhibitors of Valyl-tRNA synthetase (ValRS) operate through distinct mechanisms to impede the protein's function. Halofuginone and borrelidin are direct inhibitors; halofuginone competes with the natural substrate prolyl-tRNA, thus blocking the catalytic activity of ValRS, while borrelidin binds to ValRS and hampers its tRNA aminoacylation function, thereby preventing the synthesis of valyl-tRNA. Mupirocin, though primarily targeting isoleucyl-tRNA synthetase, can reduce the pool of aminoacylated tRNA and thus indirectly impose a bottleneck on ValRS's ability to contribute effectively to protein synthesis. GSK656, by targeting leucyl-tRNA synthetase, affects the equilibrium of the aminoacyl-tRNA synthetases, which can result in a reduced availability of charged tRNA for ValRS.

Further, cladosporin and REP3123, by inhibiting lysyl- and methionyl-tRNA synthetases respectively, can lead to an imbalance in the charged tRNA pools, which is a prerequisite for efficient ValRS function. Pyrithione zinc disrupts the activity of metalloenzymes by chelating metal ions, which are also essential for the catalytic action of ValRS. Furamidine interferes with the nucleotide pools which are fundamental for the tRNA charging process that ValRS catalyzes. Phenoxazine, by inhibiting enzymes associated with nucleic acids, can alter the synthesis and stability of tRNA molecules, thereby potentially reducing the efficacy of ValRS. Tavaborole, another inhibitor of leucyl-tRNA synthetase, can similarly affect the aminoacylation process across various tRNA synthetases, including ValRS. Lastly, cycloheximide, which inhibits eukaryotic protein synthesis, can lead to a decrease in the demand for aminoacyl-tRNA complexes, consequently diminishing the functional need for ValRS activity.